Supplement
NAD+ precursor supporting mitochondrial and repair pathways.[2906,2961,2987, etc.]
Superscript reference numbers link to the Sources bibliography.
Composite Rating
Blends evidence depth, community direction, safety friction, and completeness.
Evidence Intensity
100/100
High depth from human/RCT/meta counts
Community Direction
-15
Caution Lean • confidence Minimal
Safety Friction
100/100
High signal from adverse/interaction markers
Data Completeness
100%
Studies 12 • mentions 6 • links 22
Not medical advice. This product is for educational and informational purposes only. It does not diagnose, treat, cure, or prevent any disease and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition.
FDA disclaimer: These statements have not been evaluated by the Food and Drug Administration. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. Results may vary. Not intended for use by pregnant or nursing women, individuals under 18, or those with known medical conditions without physician consultation.
If you are experiencing a medical emergency, call 911 or your local emergency number immediately.
Goal alignment: Longevity, Energy.[584,732,956, etc.]
Dose guide: Human-study daily dose: 200 mg-1000 mg/day (higher-confidence extraction from PubMed abstracts)..[584,732,956, etc.]
Category
Cofactor
Evidence Tier
HIGH
Daily Guide
Human-study daily dose: 200 mg-1000 mg/day (higher-confidence extraction from PubMed abstracts).
Dosing Guide
Human-study daily dose: 200 mg-1000 mg/day (higher-confidence extraction from PubMed abstracts).[2906,, etc.]
Clinical Depth
Humans: 163 • RCTs: 20 • Meta: 1
Cohort / Real-World
Cohort signals: 0
Safety Markers
Adverse signals: 57 • Interactions: 47
Freshness, trend, and study timeline for this item
Status
Trend
→ Stable evidence base
Depth
364 total studies · 1 recent
Timeline
Total indexed
364
Animal-only studies
233
Human studies
163
In vitro / tissue
110
Safety adverse signals
57
Interaction signals
47
Weighted direction score: -15 (Caution Lean)
High when >=2 human meta-analyses, or >=5 human RCTs with substantial human literature volume.
Total indexed
364
Animal-only studies
233
Human studies
163
In vitro / tissue
110
Safety adverse signals
57
Interaction signals
47
Randomized trials
20
Meta-analyses
1
Distribution of evidence by study design strength
Evidence Strength: High
Composite of study volume, RCTs, and meta-analyses
PMID 40275690 • 2025 Jun
The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis.
J Cachexia Sarcopenia Muscle
Open PubMedPMID 35235774 • 2022 Mar 1
The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease.
Cell Metab
Open PubMedPMID 29599478 • 2018 Mar 29
Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy middle-aged and older adults.
Nat Commun
Benefit reports: 2
Adverse reports: 2
No-effect reports: 1
Mixed reports: 1
Unclear reports: 0
Signal confidence: 0.00
Benefits
Adverse
No Effect
Community reports split between responders and non-responders. | Step2: Insufficient empirical signal for a directional adjustment.
Reddit evidence: 0 mentions (confidence 0.00).
Amazon signal: 0 products scanned (confidence 0.00).
aggregate • unclear
Aggregate community signal: 6 directional mentions (benefit 2, adverse 2, no-effect 1, mixed 1).
Open mentionamazon
Amazon search for Nicotinamide Riboside (NR)
Rating: n/a | Reviews: n/a
Open productEvidence Sources
RCT • 2022 • Adults
Healthy and older adults.
Outcome: Raises NAD+ metabolites; mixed functional outcomes.[2906,2961,2987, etc.]
PUBMED • Humans + preclinical triage
Counts aggregated from automated literature sweep and tiering rules.
Outcome: Tier HIGH; humans 163, RCTs 20, meta-analyses 1.[2906,2961,2987, etc.]
Open sourcePMID 31278280 • 2019 Jul 5
Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults.
Sci Rep
Open PubMedPMID 31412242 • 2019 Aug 13
Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD(+) Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures.
Cell Rep
Open PubMedPMID 35998039 • 2022 Oct 10
A randomized placebo-controlled trial of nicotinamide riboside and pterostilbene supplementation in experimental muscle injury in elderly individuals.
JCI Insight
Open PubMedPMID 32320006 • 2020 Aug 1
Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans.
Am J Clin Nutr
Open PubMedPMID 37068054 • 2023 Dec 1
Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions.
J Gerontol A Biol Sci Med Sci
Open PubMedPMID 37478182 • 2023 Jul 21
What is really known about the effects of nicotinamide riboside supplementation in humans.
Sci Adv
Open PubMedPMID 29249689 • 2018 Mar 6
NAD(+) Intermediates: The Biology and Therapeutic Potential of NMN and NR.
Cell Metab
Open PubMedPMID 34497121 • 2021 Sep 14
NAD(+) supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer's disease via cGAS-STING.
Proc Natl Acad Sci U S A
Open PubMedPMID 29514064 • 2018 Mar 6
Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence.
Cell Metab
Open PubMedGNC signal: 0 products scanned (confidence 0.00) [BLOCKED].
PerimeterX / captcha block encountered.
Search fetch failed: Failed to fetch after retries: https://old.reddit.com/search.json?raw_json=1&sort=relevance&t=year&limit=12&q=%22nicotinamide%20riboside%22%20(supplement%20OR%20dosage%20OR%20stack%20OR%20side%20effects%20OR%20review)%20(subreddit%3ASupplements%20OR%20subreddit%3ANootropics%20OR%20subreddit%3ABiohackers%20OR%20subreddit%3Alongevity%20OR%20subreddit%3ANutrition%20OR%20subreddit%3AHubermanLab%20OR%20subreddit%3ASleep%20OR%20subreddit%3AFitness%20OR%20subreddit%3Aketoscience%20OR%20subreddit%3AStackAdvice)
Fallback search failed: Failed to fetch after retries: https://old.reddit.com/search.json?raw_json=1&sort=comments&t=all&limit=16&q=%22nicotinamide%20riboside%22%20(supplement%20OR%20capsule%20OR%20powder%20OR%20experience%20OR%20results%20OR%20side%20effects)
Broad search failed: Failed to fetch after retries: https://old.reddit.com/search.json?raw_json=1&sort=new&t=all&limit=16&q=nicotinamide%20riboside
Use adverse/interactions PubMed signal counts for screening; perform clinician review before high-dose or multi-drug stack use.
Human-study daily dose signal: 200 mg-1000 mg/day (confidence HIGH).
Extracted from 4 dosing mentions across 2 PubMed studies (mg/day).
Imported legacy community score: 7.0/10 (heuristic mapping confidence 1.00).
Imported legacy monthly cost signal: ~$45.00.
Legacy community note: Respected NAD+ precursor with strong safety data. Some community members prefer NMN for potency. Niagen brand has loyal following. Less "exciting" than NMN marketing-wise but solid science.
Community Sources
PUBMED • 2025 • Human evidence curation set
PMID 40275690 from J Cachexia Sarcopenia Muscle.
Outcome: See linked PubMed abstract for methods and outcomes.[2906,2961,2987, etc.]
Open sourcePUBMED • 2022 • Human evidence curation set
PMID 35235774 from Cell Metab.
Outcome: See linked PubMed abstract for methods and outcomes.[2906,2961,2987, etc.]
Open sourcePUBMED • 2018 • Human evidence curation set
PMID 29599478 from Nat Commun.
Outcome: See linked PubMed abstract for methods and outcomes.[2906,2961,2987, etc.]
Open sourcePUBMED • 2019 • Human evidence curation set
PMID 31278280 from Sci Rep.
Outcome: See linked PubMed abstract for methods and outcomes.[2906,2961,2987, etc.]
Open sourcePUBMED • 2019 • Human evidence curation set
PMID 31412242 from Cell Rep.
Outcome: See linked PubMed abstract for methods and outcomes.[2906,2961,2987, etc.]
Open sourcePUBMED • 2022 • Human evidence curation set
PMID 35998039 from JCI Insight.
Outcome: See linked PubMed abstract for methods and outcomes.[2906,2961,2987, etc.]
Open sourcePUBMED • 2020 • Human evidence curation set
PMID 32320006 from Am J Clin Nutr.
Outcome: See linked PubMed abstract for methods and outcomes.[2906,2961,2987, etc.]
Open sourcePUBMED • 2023 • Human evidence curation set
PMID 37068054 from J Gerontol A Biol Sci Med Sci.
Outcome: See linked PubMed abstract for methods and outcomes.[2906,2961,2987, etc.]
Open sourcePUBMED • 2023 • Human evidence curation set
PMID 37478182 from Sci Adv.
Outcome: See linked PubMed abstract for methods and outcomes.[2906,2961,2987, etc.]
Open sourcePUBMED • 2018 • Human evidence curation set
PMID 29249689 from Cell Metab.
Outcome: See linked PubMed abstract for methods and outcomes.[2906,2961,2987, etc.]
Open sourcePUBMED • 2021 • Human evidence curation set
PMID 34497121 from Proc Natl Acad Sci U S A.
Outcome: See linked PubMed abstract for methods and outcomes.[2906,2961,2987, etc.]
Open sourcePUBMED • 2018 • Human evidence curation set
PMID 29514064 from Cell Metab.
Outcome: See linked PubMed abstract for methods and outcomes.[2906,2961,2987, etc.]
Open source